[High-risk prostate cancer. Review by the Oncology Committee of the French Urology Association].
Fiche publication
Date publication
décembre 2011
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CORMIER Luc
Tous les auteurs :
Rozet F, Hennequin C, Fromont G, Mongiat-Artus P, Bastide C, Beuzeboc P, Cormier L, Eiss D, Peyromaure M, Richaud P, Salomon L, Soulie M
Lien Pubmed
Résumé
INTRODUCTION: Localized prostate tumors have various clinical, biological and histopathological characteristics that lead to different progression profiles. High-risk prostate cancer has been classically defined by clinical examination, PSA levels and histopathological data. High-risk prostate cancer has usually a worse outcome, but classic stratification predictive of outcome for prostate cancer is a matter of debate concerning its accuracy. METHODS: A systematic review of the literature on high-risk prostate cancer over the 15 last years was carried out on Medline database. The literature selection was based on evidence and practical considerations. RESULTS: A great deal of scientific work have been deployed to prove that high-risk prostate cancer should be approached by teamwork including radio-hormone therapy, systemic treatment with long term use of LH-RH and a radical prostatectomy with adequate lymph node dissection. Selection of patients is essential to define individualized therapeutic strategy and timing for every modality should come as a consensus of medical supported evidence. CONCLUSION: Accurate patient selection and multimodal treatment offer the best therapeutic option in high-risk prostate cancer.
Référence
Prog Urol. 2011 Dec;21(13):901-8